YZYBIO's biosimilar Y225 clinical trial application approved
YZYBIO-B (02496.HK) announced that the clinical trial application for the biosimilar Y225 has been approved by the National Medical Products Administration of China. Y225 is a bispecific antibody used for the treatment of Hemophilia A, a biosimilar to Shuyou Lile (Aimeisai Zhu Dan Kua, anti-FIX and FX) injection
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments